RU2603471C2 - Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения - Google Patents

Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения Download PDF

Info

Publication number
RU2603471C2
RU2603471C2 RU2014131285/15A RU2014131285A RU2603471C2 RU 2603471 C2 RU2603471 C2 RU 2603471C2 RU 2014131285/15 A RU2014131285/15 A RU 2014131285/15A RU 2014131285 A RU2014131285 A RU 2014131285A RU 2603471 C2 RU2603471 C2 RU 2603471C2
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
release
formulated
composition according
acetaminophen
Prior art date
Application number
RU2014131285/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2014131285A (ru
Inventor
Дэвид А. ДИЛЛ
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,332 external-priority patent/US20120135050A1/en
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2014131285A publication Critical patent/RU2014131285A/ru
Application granted granted Critical
Publication of RU2603471C2 publication Critical patent/RU2603471C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Guiding Agricultural Machines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2014131285/15A 2012-01-04 2012-08-22 Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения RU2603471C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/343,332 2012-01-04
US13/343,332 US20120135050A1 (en) 2010-07-08 2012-01-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2012/051888 WO2013103390A1 (en) 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
RU2014131285A RU2014131285A (ru) 2016-02-20
RU2603471C2 true RU2603471C2 (ru) 2016-11-27

Family

ID=48745355

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014131285/15A RU2603471C2 (ru) 2012-01-04 2012-08-22 Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения

Country Status (13)

Country Link
US (3) US8685453B2 (enExample)
JP (4) JP2015503583A (enExample)
KR (2) KR20140108675A (enExample)
AU (2) AU2012363789B2 (enExample)
BR (1) BR112014016661A8 (enExample)
CA (1) CA2856677A1 (enExample)
IL (1) IL232715A0 (enExample)
MX (1) MX2014008283A (enExample)
MY (1) MY173582A (enExample)
RU (1) RU2603471C2 (enExample)
SG (1) SG11201500407XA (enExample)
WO (1) WO2013103390A1 (enExample)
ZA (1) ZA201404606B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
BR112014001283A2 (pt) 2011-07-18 2017-02-21 Critical Care Diagnostics Inc métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
US10711230B2 (en) * 2012-03-30 2020-07-14 Givaudan Sa N-acyl proline derivatives as food flavoring compounds
EP3151834A4 (en) * 2014-06-06 2018-01-03 Wellesley Pharmaceuticals, LLC Pharmaceutical formulation for reducing frequency of urination and method of use thereof
RU2017113827A (ru) * 2014-09-24 2018-10-24 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения
KR20180054655A (ko) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
CN108348487A (zh) * 2015-09-01 2018-07-31 韦尔斯利医药有限公司 延迟释放制剂、其制备方法和用途
KR20180066113A (ko) * 2015-09-30 2018-06-18 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000032I2 (de) * 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
JP3660979B2 (ja) * 2000-09-05 2005-06-15 国立大学法人金沢大学 夜間頻尿症の治療剤、夜間頻尿症の予防剤
WO2003043655A1 (fr) * 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
AU2003211078A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
AU2003281044A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
EP1555022B1 (en) * 2002-09-21 2008-02-20 Shuyi Zhang Sustained release formulation of acetaminophen and tramadol
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
WO2006105670A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
MX2008000967A (es) * 2005-07-20 2008-03-26 Panacea Biotec Ltd Nueva composicion farmaceutica de forma de dosis de liberacion modificada que comprende inhibidor de enzima ciclooxigenasa.
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
WO2008014175A2 (en) 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
EP2190418B1 (en) * 2007-08-15 2013-10-02 Mcneil-PPC, Inc Immediate release and sustained release ibuprofen dosing regimen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
JP2018016869A (ja) * 2016-07-29 2018-02-01 日立化成株式会社 アルミニウム系多孔質体及びその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЛОПАТКИН Н.А. под ред. "Урология";// М., "ГЭОТАР-Медиа";, 2002, с.216. SAITO M. et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience// Int J Urol. 2004 Aug;11(8):592-6. *

Also Published As

Publication number Publication date
CA2856677A1 (en) 2013-07-11
RU2014131285A (ru) 2016-02-20
NZ721818A (en) 2017-07-28
MY173582A (en) 2020-02-04
NZ732149A (en) 2018-11-30
NZ626619A (en) 2017-03-31
ZA201404606B (en) 2015-11-25
AU2017203418B2 (en) 2019-01-17
US8685453B2 (en) 2014-04-01
US20150272968A1 (en) 2015-10-01
AU2017203418A1 (en) 2017-06-08
JP2018087217A (ja) 2018-06-07
BR112014016661A8 (pt) 2017-07-04
AU2012363789A2 (en) 2014-07-24
US20140154320A1 (en) 2014-06-05
WO2013103390A1 (en) 2013-07-11
JP2020037575A (ja) 2020-03-12
JP2015503583A (ja) 2015-02-02
MX2014008283A (es) 2015-03-03
AU2012363789A1 (en) 2014-07-17
AU2012363789B2 (en) 2017-04-13
US20130216620A1 (en) 2013-08-22
KR20140108675A (ko) 2014-09-12
IL232715A0 (en) 2014-07-31
SG11201500407XA (en) 2015-03-30
JP2017031172A (ja) 2017-02-09
KR20180025993A (ko) 2018-03-09
BR112014016661A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
RU2603471C2 (ru) Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8445015B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
RU2669565C2 (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
US20180344674A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20180055858A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US10792261B2 (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
US20170319520A1 (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
CN108391420A (zh) 用于减少排尿频率的组合物及其制备方法和应用
EP2612663A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CN108289891A (zh) 缓解尿频的组合物，其制造方法和应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190823